Synlogic Inc (SYBX) Gets a Buy Rating from H.C. Wainwright


In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Synlogic Inc (NASDAQ: SYBX), with a price target of $20. The company’s shares closed yesterday at $12.31.

Selvaraju observed:

“We calculate an enterprise value of $515M, which is comprised of $385M for SYNB1020 in UCD and hyperammonemia in cirrhotic liver disease and I/ O portfolio. This translates into a price objective of $20.00 per share, assuming 25.6M shares outstanding as of end-2Q19.”

According to TipRanks.com, Selvaraju is a 1-star analyst with an average return of 0.0% and a 35.6% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Biospecifics Technologies Corp, Bausch Health Companies Inc, and Synergy Pharmaceuticals Inc.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Synlogic Inc with a $21.33 average price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $18.36 and a one-year low of $7.27. Currently, Synlogic Inc has an average volume of 141.2K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Synlogic, Inc. is a clinical-stage biopharmaceutical company, which engages in drug discovery and development platform for synthetic biotic medicines. It focuses on metabolic diseases with the potential to be corrected following oral delivery of a living medicine to the gut.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts